Haematology News and Research

RSS

NeoGenomics announces launch of new NeoLAB assays to diagnose hematologic diseases

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced today the launch of its first twelve tests in a new line of "liquid biopsy" or NeoLAB assays using next generation sequencing and other advanced molecular technologies.

11 Jun 2015

EMA, ESMO and RCE joint workshop focuses on rare cancers and chordoma

To date, there is no drug approved for medical therapy of chordoma patients. Supporting research for chordoma (a very rare cancer arising from the skull base or the spine and affecting only one person in a million per year) was the focus of talks that took place on 30 April 2015 at the European Medicines Agency in London. The workshop was attended by patients, oncologists, pathologists, regulators, statisticians and industry representatives.

4 Jun 2015

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Today, Pharmacyclics LLC announced the results of the Phase III HELIOS trial (CLL3001), which found that patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who received ibrutinib (IMBRUVICA) in combination with bendamustine and rituximab (BR) experienced an 80% reduction in the risk of progression or death compared to patients receiving placebo in combination with BR.

1 Jun 2015

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Australian biopharmaceutical company Specialised Therapeutics Australia and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration has approved AKYNZEO for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy.

8 May 2015

Researchers compile new genomic interactions catalogue

New clues about diseases like inflammatory bowel disorder may be found thanks to a new genomic interactions catalogue by a group of researchers in Japan and the United Kingdom. This research will be published on May 4, 2015 in Nature Genetics.

6 May 2015

T cell expansion technology: an interview with Alexander Malykhin, CVPF, University of Pennsylvania

T cells are taken from the patient’s blood and then modified using lentivirus, adenovirus or RNA electroporation.

From Beckman Coulter Life Sciences - Flow Cytometry 5 May 2015

HSCT use varies with region

A review of almost one million haematopoietic stem cell transplantation procedures has highlighted differences in the availability of the procedure and the use of autologous and allogeneic transplants across the world.

24 Mar 2015

Findings reveal variations between countries and regions in use of HSCT procedure

Since the first experimental bone marrow transplant over 50 years ago, more than one million hematopoietic stem cell transplantations (HSCT) have been performed in 75 countries, according to new research charting the remarkable growth in the worldwide use of HSCT, published in The Lancet Haematology journal.

28 Feb 2015

Life-saving bone marrow transplants are not available to all who need them

Bone marrow (hematopoietic stem cell) transplant is a life saving treatment for patients with blood cancer that replaces blood stem cells lost to disease or chemotherapy. However, for each patient to benefit a matching donor must be found to provide the stem cells for transplant.

27 Feb 2015

Second-line bosutinib well tolerated by Japanese patients

Phase I/II clinical trial data support the use of bosutinib as second- or third-line tyrosine kinase inhibitor therapy in Japanese patients with Philadelphia chromosome-positive chronic myeloid leukaemia.

17 Feb 2015

CTI BioPharma presents data from Phase 3 trial of pacritinib in AML patients at ASH 2014

CTI BioPharma Corp. today announced data showing treatment with pacritinib, an investigational oral multikinase inhibitor in Phase 3 clinical development, preferentially killed acute myeloid leukemia (AML) cells with FLT3 mutations, overcame stromal protection and suppressed leukemic outgrowth from stroma adherent AML cells in both medium-term (7-14 days) and long-term (5-6 weeks) assays.

9 Dec 2014

$IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL$

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).

9 Dec 2014

CTI BioPharma announces upcoming presentations of pacritinib data at ASH Annual Meeting

CTI BioPharma Corp. (CTI) today announced the upcoming presentations of data highlighting pacritinib, an oral multikinase inhibitor with dual activity against JAK2 and FLT3, and tosedostat, an oral selective inhibitor of aminopeptidases, at the 56th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6-9 in San Francisco, CA.

1 Dec 2014

New active substance effectively combats Philadelphia chromosome-positive leukaemia

Haematologists from Goethe University Frankfurt, working with a Russian pharmaceutical company, have developed a new active substance that effectively combats the most aggressive forms of Philadelphia chromosome-positive leukaemia.

29 Nov 2014

Plymouth professor awarded grant to find effective treatment for patients with mantle cell lymphoma

Professor Simon Rule, Professor in Haematology at Plymouth University Peninsula Schools of Medicine and Dentistry and Consultant Haematologist at Plymouth Hospitals NHS Trust, has been awarded a significant grant by Cancer Research UK to carry out a research study into the treatment of older patients with mantle cell lymphoma.

27 Nov 2014

New correlation found between specific molecular features of CLL and patients with different prognosis

If chronic lymphocytic leukemia patients with a good or poor prognosis could be identified already at the time of diagnosis, physicians would have better possibilities to adjust their therapeutic and follow-up strategies. Now researchers at Uppsala University, together with international colleagues, have discovered a new correlation between specific molecular features of the disease and subgroups of patients with different prognosis.

6 Nov 2014

EMA's CHMP adopts final opinion on ARIAD Pharmaceuticals' Iclusig (ponatinib)

ARIAD Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted its final opinion on Iclusig (ponatinib) following the recommendations made by the Pharmacovigilance Risk Assessment Committee earlier this month.

27 Oct 2014

Elsevier honored at BMA Medical Book Awards ceremony

Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today that 28 of its professional and scholarly products were honored at the British Medical Association's annual BMA Medical Book Awards ceremony at BMA House in London on Sept. 22, 2014.

25 Sep 2014

PET-CT more accurate than conventional CT in evaluating patients with follicular lymphoma

Positron emission tomography/computed tomography (PET-CT) is more accurate than conventional CT scanning in measuring response to treatment and predicting survival in patients with follicular lymphoma, and should be used routinely in clinical practice, according to new research published in The Lancet Haematology.

19 Sep 2014

RT alone effective in decreasing dysphagia in patients with advanced esophageal cancer

Radiation therapy (RT) alone is as effective in decreasing swallowing complications experienced by advanced esophageal cancer patients as RT combined with chemotherapy, thus allowing patients to forgo chemotherapy, according to research presented today at the American Society for Radiation Oncology's 56th Annual Meeting.

16 Sep 2014